文献速递肿瘤 PET/CT

[18F]AlF-NOTA-FAPI-04 PET/CT对接受新辅助化疗的局部进展期胰腺导管腺癌患者病理缓解与生存的预测价值

Value of [18F]AlF-NOTA-FAPI-04 PET/CT for predicting pathological response and survival in patients with locally advanced pancreatic ductal adenocarcinoma receiving neoadjuvant chemotherapy.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2025-01-17

本研究纳入34例经组织学和影像学确诊的局部进展期胰腺导管腺癌(LAPDAC)患者,在新辅助化疗(NCT)前接受[18F]AlF-NOTA-FAPI-04 PET/CT扫描,NCT 4-6周期后行根治性切除,以Evans系统病理肿瘤退缩分级(TRG)评估病理缓解。结果显示原发肿瘤SUVmax、FTV、TLF及全胰腺FPV、TPF在病理良好缓解组均显著低于病理不良缓解组;FTV>54.21及TLF>290.21分别与更差的RFS和OS独立相关。

要点

  • 病理良好缓解组原发肿瘤SUVmax、FTV、TLF及全胰腺FPV、TPF均显著低于病理不良缓解组。
  • FTV>54.21与更差RFS独立相关(HR=3.24,P=0.014),TLF>290.21与更差RFS独立相关(HR=3.35,P=0.019)。
  • FTV>54.21与更差OS独立相关(HR=7.35,P=0.002),TLF>290.21与更差OS独立相关(HR=7.09,P=0.004)。

核心结论

  • [18F]AlF-NOTA-FAPI-04 PET/CT参数对预测LAPDAC患者NCT后病理TRG有良好性能,FTV和TLF是RFS和OS的独立术后预后因素。

研究设计与样本

  • 本研究纳入34例经组织病理学和影像学确诊的LAPDAC患者,NCT前接受[18F]AlF-NOTA-FAPI-04 PET/CT扫描,NCT 4-6周期后行根治性切除。
  • 病理缓解采用基于Evans系统的病理肿瘤退缩分级(TRG)评估,分为病理良好缓解(PGR,Evans III-IV)和病理不良缓解(PPR,Evans I-II)。

主要发现

  • 34例LAPDAC患者中,14例为病理良好缓解(PGR,Evans III-IV),20例为病理不良缓解(PPR,Evans I-II)。
  • PGR组原发肿瘤SUVmax、FTV、TLF及全胰腺FPV、TPF均显著低于PPR组。
  • 低分化LAPDAC的SUVmax和TLF高于高-中分化肿瘤。
  • FTV、TLF、FPV和TPF与RFS和OS密切相关。
  • 多因素分析显示,FTV>54.21和TLF>290.21分别与更差RFS(HR=3.24,P=0.014和HR=3.35,P=0.019)及更差OS(HR=7.35,P=0.002和HR=7.09,P=0.004)独立相关。

关键数值与推荐

  • 病理良好缓解定义为Evans III-IV级,病理不良缓解定义为Evans I-II级。
  • 多因素分析中FTV>54.21与更差RFS相关(HR=3.24,P=0.014),FTV>54.21与更差OS相关(HR=7.35,P=0.002)。
  • 多因素分析中TLF>290.21与更差RFS相关(HR=3.35,P=0.019),TLF>290.21与更差OS相关(HR=7.09,P=0.004)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: This study aimed to evaluate the predictive value of [18F]AlF-NOTA-FAPI-04 PET/CT for pathological response to neoadjuvant chemotherapy (NCT) and prognosis in patients with locally advanced pancreatic ductal adenocarcinoma (LAPDAC). METHODS: This study included 34 patients with histopathologically and radiologically confirmed LAPDAC who received [18F]AlF-NOTA-FAPI-04 PET/CT scans before NCT. After 4-6 cycles of NCT, these patients underwent radical resection. Pathological response to NCT was assessed by pathological tumor regression grades (TRG) based on the Evans system. PET/CT parameters were evaluated for their association with TRG, recurrence-free survival (RFS) and overall survival (OS) after NCT, including the maximum standardized uptake value (SUVmax), FAPI-avid tumor volume (FTV), total lesion FAP expression (TLF) of primary tumor, total FAPI-avid pancreatic volume (FPV) and total pancreatic FAP expression (TPF) of total pancreas. RESULTS: Of 34 patients with LAPDAC, 14 patients had a pathologic good response (PGR, Evans III-IV), and 20 patients had a pathologic poor response (PPR, Evans I-II). Both the primary tumor SUVmax, FTV and TLF, and total pancreas FPV and TPF in the PGR groups were significantly lower than those in the PPR groups. Furthermore, SUVmax and TLF were higher in poorly differentiated LAPDAC than in well-moderately differentiated neoplasms. The FTV, TLF, FPV and TPF were closely associated with RFS and OS. On multivariate analysis, patients with FTV > 54.21 and TLF > 290.21 had a worse RFS and OS, respectively (HR = 3.24, P = 0.014 and HR = 3.35, P = 0.019) and OS (HR = 7.35, P = 0.002 and HR = 7.09, P = 0.004) in LAPDAC after NCT. CONCLUSIONS: The parameters of [18F]AlF-NOTA-FAPI-04 PET/CT had the excellent performance for predicting pathologic TRG after NCT in LAPDAC. FTV and TLF were independent postoperative prognostic factors for RFS and OS for LAPDAC.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Zhang Y, Xu M, Wang Y, et al. Value of [18F]AlF-NOTA-FAPI-04 PET/CT for predicting pathological response and survival in patients with locally advanced pancreatic ductal adenocarcinoma receiving neoadjuvant chemotherapy. Eur J Nucl Med Mol Imaging. 2025. PMID: 39820598. doi:10.1007/s00259-025-07084-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。